Tolerability profile consistent with the incretin class, with gastrointestinal events most commonly reported in studies (e.g., nausea, diarrhoea, and constipation)
Patients are encouraged to speak with their GP or a specialist weight management service to explore currently available, approved treatment options
Little things, like taking the stairs and stretching in the morning, make a difference
Other documented contraindications and warnings: Pancreatitis: reported with GLP-1 agonists
The mix is studied for possibly paired or combined tissue repair effects, as BPC-157 and TB-500 operate through distinct but overlapping cell-level pathways very in the areas of angiogenesis, fibroblast start, and anti-swelling signaling
Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment // Clin